AgingResearch.NewsJoin free

RLX-201

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Cells1

Outcomes

2

Fibroblast morphology

upin human cells1

1 study

  1. RLX-201 improves fibroblast morphology in human cells.

    “RLX-201 treatment appears to alter the morphology of fibroblasts to a younger phenotype.”

    Cellsskin

    RLX-201, a Novel mTORC1 Inhibitor With Potential to Promote Skin Longevity and Cellular Health

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]1 Sep 2025

mTOR signalling

downin human cells1

1 study

  1. RLX-201 inhibits mTOR signalling in human cells.

    “RLX-201 selectively inhibited mTORC1 without suppressing mTORC2”

    Cellsskin

    RLX-201, a Novel mTORC1 Inhibitor With Potential to Promote Skin Longevity and Cellular Health

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]1 Sep 2025

More on mTOR signalling

Latest

Related